Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation, part III: intravenous immunoglobulin.

Susan Givens Bell1

  • 1University of South Florida, Tampa, USA.

Neonatal Network : NN
|June 6, 2006
PubMed
Summary

Intravenous immunoglobulin (IVIG) therapy shows no clear benefit in preventing neonatal sepsis and its effectiveness in treatment remains uncertain. Further research is needed to determine its true value against costs and explore alternative immunotherapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enteral Iron Supplementation.

Neonatal network : NN·2026
Same author

Ondansetron: A Novel Treatment to Reduce the Severity of Neonatal Opioid Withdrawal Syndrome?

Neonatal network : NN·2025
Same author

Second-Line Medications for Neonatal Opioid Withdrawal Syndrome/Neonatal Abstinence Syndrome.

Neonatal network : NN·2025
Same author

The Evidence-Based Practice Process Steps 4, 5, and 6: Integration, Evaluation, and Dissemination.

Neonatal network : NN·2024
Same author

Step 3: Critical Appraisal of Evidence-Expert Opinion.

Neonatal network : NN·2024
Same author

Step 3: Critically Appraising Evidence: Case-Control Studies.

Neonatal network : NN·2023

Area of Science:

  • Neonatal immunology
  • Immunotherapy
  • Pediatric infectious diseases

Background:

  • Neonatal sepsis poses a significant threat to infant health.
  • Intravenous immunoglobulin (IVIG) therapy has been explored as a potential treatment and preventative measure.
  • The current evidence on IVIG efficacy in neonates is inconclusive.

Purpose of the Study:

  • To evaluate the efficacy of IVIG in preventing neonatal sepsis.
  • To assess the uncertain role of IVIG in treating neonatal sepsis.
  • To inform future research directions for neonatal immunotherapy.

Main Methods:

  • Review of existing studies on IVIG for neonatal sepsis prevention and treatment.
  • Consideration of cost-effectiveness and long-term outcomes.
  • Highlighting the need for ongoing large-scale trials like the International Neonatal Immunotherapy Study.

Main Results:

  • IVIG therapy does not appear to be efficacious in preventing neonatal sepsis.
  • A minor reduction in sepsis rates without mortality benefit must be weighed against therapy costs.
  • The efficacy of IVIG in treating established neonatal sepsis remains uncertain.

Conclusions:

  • The value of IVIG for neonatal sepsis prevention is questionable due to lack of mortality reduction and high costs.
  • Further studies are recommended, focusing on specific antibody concentrations and cost-effectiveness.
  • The International Neonatal Immunotherapy Study is expected to provide definitive answers on IVIG effectiveness.

Related Experiment Videos